IGLV3 25 | ENSG00000211659 | NCBI 28793

Details for: IGLV3 25

Gene ID: 28793

Gene Type: Other - A known gene or region type that lacks a specific category. Includes immunoglobulin (Ig), T-cell receptor (TCR) gene segments, and repetitive elements.

Symbol: IGLV3 25

Ensembl ID: ENSG00000211659

Description: immunoglobulin lambda variable 3-25

Cell Significance Landscape

Display Count:

Associated with

Adaptive immune system
(R-HSA-1280218)
Anti-inflammatory response favouring leishmania parasite infection
(R-HSA-9662851)
Antigen activates b cell receptor (bcr) leading to generation of second messengers
(R-HSA-983695)
Binding and uptake of ligands by scavenger receptors
(R-HSA-2173782)
Cd22 mediated bcr regulation
(R-HSA-5690714)
Cell surface interactions at the vascular wall
(R-HSA-202733)
Classical antibody-mediated complement activation
(R-HSA-173623)
Complement cascade
(R-HSA-166658)
Creation of c4 and c2 activators
(R-HSA-166786)
Disease
(R-HSA-1643685)
Fc epsilon receptor (fceri) signaling
(R-HSA-2454202)
Fceri mediated ca+2 mobilization
(R-HSA-2871809)
Fceri mediated mapk activation
(R-HSA-2871796)
Fceri mediated nf-kb activation
(R-HSA-2871837)
Fcgamma receptor (fcgr) dependent phagocytosis
(R-HSA-2029480)
Fcgr3a-mediated il10 synthesis
(R-HSA-9664323)
Fcgr3a-mediated phagocytosis
(R-HSA-9664422)
Fcgr activation
(R-HSA-2029481)
Hemostasis
(R-HSA-109582)
Immune system
(R-HSA-168256)
Immunoregulatory interactions between a lymphoid and a non-lymphoid cell
(R-HSA-198933)
Infectious disease
(R-HSA-5663205)
Initial triggering of complement
(R-HSA-166663)
Innate immune system
(R-HSA-168249)
Leishmania infection
(R-HSA-9658195)
Leishmania parasite growth and survival
(R-HSA-9664433)
Leishmania phagocytosis
(R-HSA-9664417)
Parasite infection
(R-HSA-9664407)
Parasitic infection pathways
(R-HSA-9824443)
Potential therapeutics for sars
(R-HSA-9679191)
Regulation of actin dynamics for phagocytic cup formation
(R-HSA-2029482)
Regulation of complement cascade
(R-HSA-977606)
Role of lat2/ntal/lab on calcium mobilization
(R-HSA-2730905)
Role of phospholipids in phagocytosis
(R-HSA-2029485)
Sars-cov infections
(R-HSA-9679506)
Scavenging of heme from plasma
(R-HSA-2168880)
Signaling by the b cell receptor (bcr)
(R-HSA-983705)
Vesicle-mediated transport
(R-HSA-5653656)
Viral infection pathways
(R-HSA-9824446)
Adaptive immune response
(GO:0002250)
Antigen binding
(GO:0003823)
Blood microparticle
(GO:0072562)
Extracellular region
(GO:0005576)
Immune response
(GO:0006955)
Immunoglobulin complex
(GO:0019814)
Plasma membrane
(GO:0005886)

Significant Cells

Cell Significance Index (CSI) scores for the chosen context(s)

non-classical monocyte CL0000875

CSI 5.41

rCSI 8.67%

PRS 96.7
B cell CL0000236

CSI 4.45

rCSI 5.96%

PRS 92.46
plasmablast CL0000980

CSI 3.73

rCSI 2.94%

PRS 94.9
CD4-positive, alpha-beta T cell CL0000624

CSI 3.01

rCSI 3.85%

PRS 94.46
classical monocyte CL0000860

CSI 2.91

rCSI 4.32%

PRS 96.11
IgA plasma cell CL0000987

CSI 2.85

rCSI 2.92%

PRS 94.11
IgG plasma cell CL0000985

CSI 2.61

rCSI 3.12%

PRS 95.78
natural killer cell CL0000623

CSI 2.13

rCSI 4.12%

PRS 93.82
dendritic cell CL0000451

CSI 1.69

rCSI 2.09%

PRS 92.68

Cell ID: Standard Cell Ontology term used for mapping and comparing cells across experiments. Ensures consistency in analyzing cellular functions across tissues.
Fold Change: Represents the ratio of the current Cell Significance Index to the Cell Significance Index Threshold, indicating how much the gene expression has changed compared to a baseline.
Cell Significance Index: Reflects how strongly a gene is expressed in this specific cell.

Network Configuration

Explore relationships of the current gene. Select an Interaction Source: 'ONTOLOGY' for shared pathways (GO/Reactome) or 'STRING' for protein-protein interactions. Further refine by selecting context genes and comparing Cell Significance Index (CSI) scores between baseline and target cell types and their specific contexts.

Context Genes (max 20):

Interaction Source:

Pathway Categories (for ONTOLOGY source):

Baseline Cell Type:

Baseline Cell Context(s): Comma-separated if multiple.

Target Cell Type:

Target Cell Context(s): Comma-separated if multiple.

Legend:

Query Gene
Node Color (Target Cell CSI, relative to current network):
- Very High
- High
- Medium
- Low
- Very Low
- CSI N/A
Node Size: Proportional to Target Cell CSI magnitude
STRING PPI Edge
Shared Pathway Edge (ONTOLOGY)

Loading network (please wait)...

Other Information

This section provides additional information about the gene, including a description generated by an AI language model and details about associated proteins.

Description

## Summary [IGLV3 25](/details-gene/28793) (Immunoglobulin Lambda Variable 3-25) is a gene segment located on chromosome 22 that encodes a variable region of the immunoglobulin lambda light chain. As a key component of the antibody repertoire, its primary molecular function is [antigen binding (GO:0003823)](https://www.ebi.ac.uk/QuickGO/term/GO:0003823), contributing to the diversity and specificity of the humoral immune response. **Overall**, its expression is highly significant in various immune cell populations, most notably in [non-classical monocyte](/details-cell/CL0000875), [B cell](/details-cell/CL0000236), and [plasmablast](/details-cell/CL0000980). This expression pattern suggests a critical role not only in the generation of antibodies by the B cell lineage but also in the effector functions mediated by myeloid cells, consistent with its deep involvement in the [adaptive immune system (R-HSA-1280218)](https://reactome.org/content/detail/R-HSA-1280218). ## Cellular Roles and Expression Landscape The expression profile of [IGLV3 25](/details-gene/28793) firmly places it within the immune system, with high significance across both lymphoid and myeloid lineages. Its prominent role in the B cell lineage is expected, with high Cell Significance Index (CSI) scores in [B cell](/details-cell/CL0000236) (CSI: 4.45), antibody-secreting [plasmablast](/details-cell/CL0000980) (CSI: 3.73), and both [IgA plasma cell](/details-cell/CL0000987) and [IgG plasma cell](/details-cell/CL0000985). This indicates its frequent utilization in the generation of the antibody repertoire. Intriguingly, the highest significance score for [IGLV3 25](/details-gene/28793) is observed in [non-classical monocyte](/details-cell/CL0000875) (CSI: 5.41), followed by [classical monocyte](/details-cell/CL0000860) (CSI: 2.91). This is likely not due to endogenous gene expression but rather reflects the binding of IGLV3-25-containing antibodies to Fc receptors on the surface of these phagocytic cells. This suggests that antibodies incorporating this specific lambda chain are particularly important for mediating monocyte effector functions. The gene also shows relevance in other innate and adaptive immune cells, including [CD4-positive, alpha-beta T cell](/details-cell/CL0000624) and [natural killer cell](/details-cell/CL0000623), highlighting its broad impact on immune cell interactions and functions. ## Pathways and Molecular Function The functional annotations for [IGLV3 25](/details-gene/28793) are consistent with its role as a component of the adaptive immune response. Gene Ontology terms classify its function within the [adaptive immune response (GO:0002250)](https://www.ebi.ac.uk/QuickGO/term/GO:0002250) and specify its molecular role as [antigen binding (GO:0003823)](https://www.ebi.ac.uk/QuickGO/term/GO:0003823). It is a component of the [immunoglobulin complex (GO:0019814)](https://www.ebi.ac.uk/QuickGO/term/GO:0019814), which is found in the [extracellular region (GO:0005576)](https://www.ebi.ac.uk/QuickGO/term/GO:0005576). Reactome pathway analysis provides a more granular view of its functional context. The gene is integral to B cell biology, including [signaling by the B cell receptor (BCR) (R-HSA-983705)](https://reactome.org/content/detail/R-HSA-983705). More importantly, the pathways strongly support its role in antibody effector functions, which aligns with its high significance in monocytes. These pathways include [Fcgamma receptor (FCGR) dependent phagocytosis (R-HSA-2029480)](https://reactome.org/content/detail/R-HSA-2029480) and [classical antibody-mediated complement activation (R-HSA-173623)](https://reactome.org/content/detail/R-HSA-173623). The annotations also link [IGLV3 25](/details-gene/28793) to responses against specific pathogens, such as in [Leishmania infection (R-HSA-9658195)](https://reactome.org/content/detail/R-HSA-9658195) and [Sars-cov infections (R-HSA-9679506)](https://reactome.org/content/detail/R-HSA-9679506), suggesting its potential preferential use in immunity against certain classes of infectious agents. ## Research Directions The data suggest that [IGLV3 25](/details-gene/28793) is not merely a random component of the antibody pool but may possess characteristics that favor specific immune functions, particularly those involving myeloid cells. **Testable Hypotheses:** 1. The high significance of [IGLV3 25](/details-gene/28793) in [non-classical monocyte](/details-cell/CL0000875) suggests that lambda light chains utilizing this V-gene segment confer structural properties to antibodies that enhance their affinity for Fc-gamma receptors (FcγRs) on these cells, thereby promoting more efficient antibody-dependent cellular phagocytosis (ADCP) or other effector functions. 2. The inclusion of [IGLV3 25](/details-gene/28793) in pathways related to specific infectious diseases like Leishmania and SARS-CoV suggests that this gene segment is preferentially selected during the humoral response to certain pathogens, potentially because it is well-suited to form a binding pocket for key antigens from these organisms. **Proposed Experiment:** To test the first hypothesis regarding enhanced monocyte effector function, one could perform a comparative functional assay. A recombinant monoclonal antibody (mAb) featuring the [IGLV3 25](/details-gene/28793) variable region could be engineered, alongside a control mAb with an identical heavy chain and a different, commonly used lambda variable region. Target particles or cells opsonized with these two different mAbs would then be co-cultured with isolated primary human [non-classical monocyte](/details-cell/CL0000875). The efficiency of phagocytosis could be quantified using flow cytometry or high-content imaging. A significant increase in phagocytosis mediated by the IGLV3-25-containing mAb would support the hypothesis that this variable segment contributes to superior effector function. **Therapeutic Potential:** As a germline gene segment, [IGLV3 25](/details-gene/28793) itself is not a direct therapeutic target for inhibition or activation. However, its preferential usage in certain pathological contexts could be exploited. For instance, if antibodies incorporating [IGLV3 25](/details-gene/28793) are found to be clonally expanded in specific autoimmune diseases or cancers, they could serve as valuable biomarkers for disease activity. Furthermore, identifying the antigens targeted by these specific antibodies could uncover novel therapeutic targets. In antibody engineering, understanding the biophysical properties conferred by the [IGLV3 25](/details-gene/28793) segment could inform the design of monoclonal antibodies with enhanced effector functions for use in oncology or infectious disease.

Disclaimer: This in-silico analysis is generated by an AI language model and may contain inaccuracies or hallucinations. However, it is cross-referenced with curated gene expression data from major biological sources. Please verify the information before use.